The ongoing soap opera that was the Bayer pursuit of Monsanto (MON) appears to have ended with a $66 billion dollar deal, or $128 a share. Monsanto's stock, however, is still trading near $107. Bernstein's Jonas Oxgaard and team spoke with investors before the deal was made official and offer some insights why that may be: ...we conducted an investor survey with 74 qrespondents in an attempt to gauge the deal's success probability and any other investor sentiment. 80% believe that Monsanto and Bayer will agree to a deal.
https://finance.yahoo.com/news/american-dream-city-living-built-133506175.html
GO MON
"PEACE"
$$$$$$ I'VE GOT MINE $$$$$$
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM